Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies Holdings, a clinical-stage medical biotechnology company, has announced that its registration statement on Form S-1 for a proposed public direct listing has been declared effective by the Securities and Exchange Commission (SEC). The company's common stock is scheduled to begin trading on the Nasdaq Global Market under the ticker symbol 'NTHI' on March 26, 2025.
Interested parties can access the prospectus related to the registration statement through the SEC's EDGAR website or via NeOnc's investor relations page at neonctech.com.
NeOnc Technologies Holdings, Inc. (upcoming NASDAQ: NTHI) has appointed Dr. Alan Chiang to its Board of Directors. Dr. Chiang, a practicing neurosurgeon at Fu Jen Catholic University Hospital and Associate Professor of Neurosurgery, brings expertise in minimally invasive spine surgery, brain tumor treatment, and biotechnology innovation.
Currently serving at Fu Jen Catholic University Hospital in New Taipei City, Taiwan, Dr. Chiang previously held key positions at Mackay Memorial Hospital, including Chief of Neurosurgery Division and Deputy Chairman of Surgery Department. He holds a Ph.D. from the Free University of Berlin and conducts research on brain cancer, focusing on WWOX and Sonic Hedgehog (SHH) pathways in glioma and glioblastoma.
As an entrepreneur, Dr. Chiang founded Neucen Biomedical Inc. and Orion Biotech Inc. His appointment aims to support NeOnc's advancement of their patented drug, NEO100, targeting brain and central nervous system diseases.
NeOnc Technologies Holdings (future NASDAQ: NTHI) has appointed former Beverly Hills Mayor Jimmy Delshad to its Board of Directors. Delshad, currently serving as global ambassador for Cedars Sinai International, brings extensive experience in management, technology, and community engagement.
As the first Iranian American mayor of Beverly Hills, Delshad is known for implementing 'Smart City' initiatives and has over 20 years of consulting experience across multiple sectors. He holds a computer science degree from UC (CSUN) and serves as Chairman of American International Business, Inc.
The appointment aims to leverage Delshad's expertise in strategic growth, fundraising, and community relations to support NeOnc's mission of developing treatments for brain and Central Nervous System diseases.
NeOnc Technologies Holdings (future NASDAQ: NTHI), a clinical-stage medical biotechnology company, has appointed Bader Almonawer to its Board of Directors. Almonawer, currently Managing Partner at Arabian Group, brings over a decade of experience in venture capital, investment banking, and business consulting.
His career includes founding Oasis Capital, a VC fund that invested in successful early-stage startups, and positions at McKinsey & Company, World Bank, Wafra Inc.'s Alternative Investments Division, and Citigroup's M&A advisory division. The appointment aims to leverage his expertise as NeOnc prepares for its public listing and expansion of clinical trials, particularly in the Gulf region.
The company focuses on developing treatments for brain cancer and central nervous system diseases. Almonawer holds degrees from Penn State University, Cornell University, and MIT, where he received various honors including the Halaby Fellowship.
NeOnc Technologies Holdings (NTHI) has appointed Dr. Steven L. Giannotta, former Chair of Neurological Surgery at USC, to its Board of Directors. Dr. Giannotta brings over 40 years of expertise in cerebrovascular and cranial base surgery to the clinical-stage medical biotechnology company.
Dr. Giannotta is internationally recognized for pioneering 'hyperdynamic therapy' for cerebral vasospasm and has performed over 1,000 intracranial aneurysm surgeries. His research focuses on cerebral blood flow, ischemia, and ethnic differences in cerebrovascular disorders.
The appointment aligns with NeOnc's mission of pursuing innovative solutions in neurosurgical care. Dr. Giannotta joined USC's Department of Neurosurgery in 1980 and has developed a comprehensive, multidisciplinary approach to complex cerebrovascular conditions.
NeOnc Technologies Holdings (upcoming NASDAQ: NTHI), a clinical-stage medical biotechnology company, has appointed Dr. Victoria Medvec to its Board of Directors. Dr. Medvec, CEO of Medvec and Associates and advisor to Fortune 100 companies, brings extensive experience in strategic partnerships, mergers and acquisitions, and regulatory negotiations.
Dr. Medvec currently holds the Adeline Barry Davee Professorship at Northwestern University's Kellogg School of Management and has advised major life sciences companies including Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer, and Sanofi. The appointment aims to strengthen NeOnc's position as it works toward commercializing central nervous system therapeutics and developing treatments for brain tumors.
NeOnc Technologies has completed an $18.5 million financing round, increasing its post-money valuation by 214% to approximately $220 million. This funding supports Phase I and II clinical trials of its NEO™ technology for brain cancer treatment, which has shown promising results in overcoming the blood-brain barrier. The financing includes $4.5 million in new equity investment and converts $14 million of debt to equity, eliminating all short-term debt. NeOnc's intellectual property portfolio comprises 135 patents, and the company has secured FDA Fast-Track and Orphan Drug statuses for its leading candidates, enhancing the therapeutic potential and market opportunities. The global CNS and brain tumor drug markets are projected to grow significantly, providing promising prospects for NeOnc's innovative therapies.
NeOnc Technologies has been awarded the Breakthrough Medical Technology Achievement Award by the California Investment Forum (CIF) for its innovative approaches in treating brain and central nervous system diseases. The award was presented by California State Treasurer Fiona Ma at the 2024 CIF Innovation Awards in Anaheim, marking NeOnc's recognition from a global pool of participants. Founder and CEO Dr. Thomas Chen highlighted the potential of NeOnc’s NEO™ drug development platform to improve treatments for brain tumors and other cancers. The company’s patented intranasal delivery system, which bypasses the blood-brain barrier, was also showcased. NeOnc's portfolio includes 135 U.S. and international patents, secured from the University of Southern California.
NeOnc Technologies Holdings, a clinical-stage biopharmaceutical company, will present at the California Investment Forum, nominated for the Breakthrough Medical Technology Achievement Award. The forum will connect NeOnc with investors and partners, highlighting its intranasal delivery system technology designed to enhance treatment efficacy for brain and central nervous system diseases.